UY35981A - Métodos para tratar el dolor asociado a la osteoartritis en una articulación con una formulación tópica de un compuesto de espirooxindol - Google Patents
Métodos para tratar el dolor asociado a la osteoartritis en una articulación con una formulación tópica de un compuesto de espirooxindolInfo
- Publication number
- UY35981A UY35981A UY0001035981A UY35981A UY35981A UY 35981 A UY35981 A UY 35981A UY 0001035981 A UY0001035981 A UY 0001035981A UY 35981 A UY35981 A UY 35981A UY 35981 A UY35981 A UY 35981A
- Authority
- UY
- Uruguay
- Prior art keywords
- methods
- compound
- osteoarthritis
- spyrooxindol
- articulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
Métodos para tratar el dolor asociado a la osteoartritis en una articulación de un mamífero con una composición farmacéutica que comprende un compuesto de espiro-oxindol que tiene la siguiente fórmula: Los métodos proveen una penetración excelente del compuesto de espiro-oxindol en la membrana sinovial de la articulación afectada, que es útil para reducir de manera eficaz la intensidad del dolor y/o para aliviar el dolor, con una exposición sistémica mínima o insignificante.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461936221P | 2014-02-05 | 2014-02-05 | |
US201462026554P | 2014-07-18 | 2014-07-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY35981A true UY35981A (es) | 2015-08-31 |
Family
ID=52544587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001035981A UY35981A (es) | 2014-02-05 | 2015-02-05 | Métodos para tratar el dolor asociado a la osteoartritis en una articulación con una formulación tópica de un compuesto de espirooxindol |
Country Status (4)
Country | Link |
---|---|
US (1) | US20150216794A1 (es) |
TW (1) | TW201540299A (es) |
UY (1) | UY35981A (es) |
WO (1) | WO2015120151A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
WO2017218957A1 (en) * | 2016-06-16 | 2017-12-21 | Teva Pharmaceuticals International Gmbh | Solid state forms of spiro-oxindole compounds |
GB201706969D0 (en) * | 2017-05-02 | 2017-06-14 | Medherant Ltd | Formulation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
MX343215B (es) * | 2010-02-26 | 2016-10-27 | Xenon Pharmaceuticals Inc | Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos. |
-
2015
- 2015-02-05 WO PCT/US2015/014627 patent/WO2015120151A1/en active Application Filing
- 2015-02-05 UY UY0001035981A patent/UY35981A/es not_active Application Discontinuation
- 2015-02-05 TW TW104103958A patent/TW201540299A/zh unknown
- 2015-02-05 US US14/614,895 patent/US20150216794A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20150216794A1 (en) | 2015-08-06 |
WO2015120151A1 (en) | 2015-08-13 |
TW201540299A (zh) | 2015-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP20005581A (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp | |
CL2018003588A1 (es) | Uso de inhibidores de miostatina y terapias de combinación. | |
CO2018006714A2 (es) | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa | |
AR102553A1 (es) | Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit | |
CL2016002516A1 (es) | “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct | |
CL2016002812A1 (es) | Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación. | |
CL2015002710A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso. | |
CO2019005059A2 (es) | Inhibidores de magl | |
CO2019005038A2 (es) | Inhibidores de magl | |
BR112015023760A2 (pt) | compostos e composições terapêuticas | |
CL2019003398A1 (es) | Inhibidores pirazólicos de magl. | |
CL2016000009A1 (es) | Tratamiento de rosacea papulopustular con ivermectina. | |
SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
CL2017002170A1 (es) | Desacetoxitubulisina h y análogos de esta. | |
DOP2016000336A (es) | Derivados de isoindolina para uso en el tratamiento de una infeccion viral | |
CL2019001996A1 (es) | Usos terapéuticos de un polvo de insectos. | |
CO7141430A2 (es) | Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación | |
CL2019002574A1 (es) | Moduladores de la expresión de pcsk9. | |
DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
CR20150653A (es) | Compuestos nuevos para el tratamiento del cáncer | |
UY36373A (es) | Compuestos para usarse en el tratamiento antihelmíntico | |
SV2016005293A (es) | Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2 | |
EA201791814A1 (ru) | Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления | |
CL2015001446A1 (es) | Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido. | |
UY35981A (es) | Métodos para tratar el dolor asociado a la osteoartritis en una articulación con una formulación tópica de un compuesto de espirooxindol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20220610 |